The development of anti-tumour necrosis factor (TNF-) therapy has been a milestone in the
treatment of rheumatoid arthritis (RA) and is proving equally important in other inflammatory …

Background Secukinumab is an anti–interleukin-17A monoclonal antibody that has been
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted …

Background Interleukin 17A is a proinflammatory cytokine that is implicated in the
pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous …

Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …

Objective To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-
interleukin-17A antibody, in patients with rheumatoid arthritis (RA). Methods Patients (n …

Objectives To evaluate the effect of subcutaneous (sc) secukinumab, an interleukin-17A
inhibitor, on clinical signs and symptoms and radiographic progression in patients with …

Objective To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical
signs and symptoms and radiographic changes through 2 years in patients with ankylosing …

The evaluation of soil aggregate stability and water retention is important in the assessment
of soil management options. A 3-year study was conducted in 1999 to determine the effects …

Background Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …

Objectives To assess long-term efficacy, safety and tolerability of secukinumab up to 104
weeks in patients with active PsA. Methods Patients with PsA (n= 397) were randomized to …